Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322394 | 0.82 | DCPS (0.30) | DCPSADORA2A | |
| SCHEMBL536979 | 0.80 | DPP4 (0.33) | ADORA2A | |
| SCHEMBL7452627 | 0.78 | CDK2 (0.32) | — | |
| SCHEMBL536796 | 0.78 | — | — | |
| SCHEMBL4058595 | 0.78 | — | — | |
| SCHEMBL2258938 | 0.78 | — | — | |
| SCHEMBL3318704 | 0.78 | — | — | |
| SCHEMBL1025894 | 0.74 | CCNA2 (0.37) | — | |
| SCHEMBL537482 | 0.74 | — | — | |
| SCHEMBL3235806 | 0.74 | NOS1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1816 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118355122-A | Aptamer for personal healthcare applications | 宝洁公司 | 2024-07-16 | — | — | CN | claimed |
| CN-113924492-B | Detection of microbial endotoxin in oral samples using an aptamer | 宝洁公司 | 2024-07-16 | — | — | CN | claimed |
| CN-118339295-A | Aptamer for personal healthcare applications | 宝洁公司 | 2024-07-12 | — | — | CN | claimed |
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | claimed |
| US-20240209375-A1 | Aptamers For Personal Health Care Applications | PROCTER & GAMBLE (US) | 2024-06-27 | — | — | US | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| CN-117715942-A | Enhanced targeting using antibody-oligonucleotide conjugates | 代码生物疗法公司 | 2024-03-15 | — | — | CN | claimed |
| EP-4301859-A1 | ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Code Biotherapeutics, Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| US-11859187-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2024-01-02 | — | — | US | claimed |
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-10-26 | — | — | US | claimed |
| EP-0519463-A1 | Synthetic, catalytic oligonucleotides | EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIE (EMBL) (DE) | 1992-12-23 | — | — | EP | claimed |
| US-5155112-A | Antiviral agents; Herpes virus | GLAXO GROUP LIMITED (GB) | 1992-10-13 | — | — | US | claimed |
| US-5142051-A | Viricides special for mutants of herpes viruses | CESKOSLOVENSKA AKADEMIE VED (CS) | 1992-08-25 | — | — | US | claimed |
| US-4968674-A | Antiviral carbocyclic purine nucleosides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-11-06 | — | — | US | claimed |
| EP-0253412-B1 | N-PHOSPHONYLMETHOXYALKYL DERIVATIVES OF PYRIMIDINE AND PURINE BASES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFROM WITH ANTIVIRAL ACTIVITY | Ceskoslovenska akademie ved (CS) | 1990-10-31 | — | — | EP | claimed |
| EP-0345076-A1 | Cyclopentane derivatives | GLAXO GROUP LIMITED (GB) | 1989-12-06 | — | — | EP | claimed |
| EP-0285884-A2 | Process to produce 2', 3'-Dideoxynucleosides | Bristol-Myers Squibb Company (US) | 1988-10-12 | — | — | EP | claimed |
| EP-0278501-A2 | Nucleotide analogs, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-08-17 | — | — | EP | claimed |
| EP-0253412-A2 | N-Phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and pharmaceutical compositions therefrom with antiviral activity | Ceskoslovenska akademie ved (CS) | 1988-01-20 | — | — | EP | claimed |
| EP-0236935-A2 | Carboxylic purine nucleosides, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | SLC29A1, SLC29A2, PNP | DCPS 73/4885ADORA2A 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.